XHKG
2552
Market cap290mUSD
Oct 09, Last price
2.23HKD
1D
-2.62%
1Q
-16.48%
IPO
-72.77%
Name
Hua Medicine
Chart & performance
P/E
1.76
P/S
3.95
EPS
1.08
Div yield, %
—
Shrs. gr., 5y
1.11%
Rev. gr., 5y
123.22%
Revenues
480m
+87.65%
Net income
1.08b
P
CFO
-52m
L-87.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.
Key people
Non-Executive Chairman of the Board · since 2018
Li Chen
Chief Executive Officer, Founder, Executive Director · since 2022
Yi Zhang
Senior Vice President - Pharma Development, Chief Medical Officer, Executive Director · since 2024
Fuxing Tang
Chief Technology Officer, Vice President - Chemical Manufacturing Control Department, Head of Research and Development - USA · since 2020
Changhong Li
Chief Scientific Officer · since 2022
Qing Dong
Vice President - Pharmaceutical Commercialization Division · since 2022
Ying Xie
Vice President - Quality Assurance Division, Chief Quality Officer · since 2023
Chien Cheng Lin
Executive Vice President, Chief Strategy Officer, Executive Director · since 2023
Company Secretary · since 2019
Fangxin Li
Non-Executive Director · since 2023
Yiu Leung Cheung
Independent Non-Executive Director · since 2023
Independent Non-Executive Director · since 2018
Independent Non-Executive Director · since 2018
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||